[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 20 of about 20
1. Nonomura N, Oka D, Nishimura K, Nakayama M, Inoue H, Mizutani Y, Miki T, Okuyama A: Paclitaxel, ifosfamide, and nedaplatin (TIN) salvage chemotherapy for patients with advanced germ cell tumors. Int J Urol; 2007 Jun;14(6):527-31
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paclitaxel, ifosfamide, and nedaplatin (TIN) salvage chemotherapy for patients with advanced germ cell tumors.
  • We investigated the usefulness of a paclitaxel, ifosfamide, and nedaplatin (TIN) regimen as salvage therapy for patients with advanced testicular germ cell tumors (GCTs).
  • The treatment was performed as salvage therapy for cases refractory to therapies, such as bleomycin, etoposide and cisplatin, and irinotecan with nedaplatin.
  • RESULTS: Seven out of eight patients achieved a disease-free status after chemotherapy, followed by surgical resection of the residual tumor.
  • Six of the seven patients have continued to show no evidence of disease after salvage therapy, with a median follow-up period of 27 months, but one patient developed a 'growing teratoma syndrome' in the mediastinum 31 months after TIN chemotherapy.
  • All patients developed grade 4 leukocytopenia.
  • Only one patient developed grade 2 sensory neuropathy and no patient developed nephrotoxicity.
  • CONCLUSION: The TIN regimen was efficacious and well-tolerated as salvage chemotherapy for Japanese patients with advanced GCTs.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Neoplasms, Germ Cell and Embryonal / drug therapy. Salvage Therapy / methods. Testicular Neoplasms / drug therapy
  • [MeSH-minor] Acute Kidney Injury / chemically induced. Acute Kidney Injury / prevention & control. Adult. Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Agents, Alkylating / adverse effects. Antineoplastic Agents, Phytogenic / administration & dosage. Antineoplastic Agents, Phytogenic / adverse effects. Humans. Ifosfamide / administration & dosage. Ifosfamide / adverse effects. Male. Organoplatinum Compounds / administration & dosage. Organoplatinum Compounds / adverse effects. Paclitaxel / administration & dosage. Paclitaxel / adverse effects. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17593098.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Phytogenic; 0 / Organoplatinum Compounds; 8UQ3W6JXAN / nedaplatin; P88XT4IS4D / Paclitaxel; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


2. Sugiyama T, Hirano Y, Ushiyama T, Suzuki K, Fujita K, Ohmi Y: [Burned-out testicular tumor: a case report]. Hinyokika Kiyo; 2000 Nov;46(11):829-32
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Computed tomography showed a large mass in his left retroperitoneal space.
  • Only fibrous tissue, small calcified areas, and hyaline bodies were found.
  • As tumor markers were normalized after 3 courses of chemotherapy with bleomycin, etoposide, and cisplatine, the retroperitoneal mass was removed with the left kidney.
  • It consisted of embryonal carcinoma, mature teratoma, and yolk sac tumor.
  • One course of adjuvant chemotherapy was done and the patient has since been free from recurrence.
  • [MeSH-major] Carcinoma, Embryonal / secondary. Endodermal Sinus Tumor / secondary. Retroperitoneal Neoplasms / secondary. Teratoma / secondary. Testicular Neoplasms / diagnosis. Testicular Neoplasms / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / administration & dosage. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Etoposide / administration & dosage. Humans. Male. Neoplasms, Multiple Primary. Orchiectomy. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11193307.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


3. Wolff EF, Hughes M, Merino MJ, Reynolds JC, Davis JL, Cochran CS, Celi FS: Expression of benign and malignant thyroid tissue in ovarian teratomas and the importance of multimodal management as illustrated by a BRAF-positive follicular variant of papillary thyroid cancer. Thyroid; 2010 Sep;20(9):981-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of benign and malignant thyroid tissue in ovarian teratomas and the importance of multimodal management as illustrated by a BRAF-positive follicular variant of papillary thyroid cancer.
  • BACKGROUND: The most common type of ovarian germ cell tumor is the teratoma.
  • Thyroid tissue, both benign and malignant, may be a component of an ovarian teratoma.
  • Here we review this topic and illustrate major features by presenting multimodal management of a patient with BRAF-positive disseminated follicular thyroid cancer arising in an ovarian teratoma.
  • SUMMARY: Malignant thyroid tissue is often difficult to distinguish from benign thyroid tissue arising in ovarian teratomas.
  • Preoperatively, an elevated thyroglobulin (Tg) level, laboratory or clinical evidence of hyperthyroidism, or ultrasonography appearance of "struma pearl" should prompt referral to oncologist for surgical management of a possibly malignant ovarian teratoma.
  • Postoperatively, tumor tissue should be referred to pathologists experienced with differentiating benign from malignant struma ovarii.
  • Once diagnosed, treatment of this rare condition should be handled by a team of specialists with combined treatment modalities.
  • We cared for woman with disseminated thyroid cancer arising in an ovarian teratoma whose history illustrates the complexity of managing ovarian teratomas with malignant thyroid tissue.
  • A post-(131)I treatment scan revealed diffuse uptake throughout the abdomen.
  • She then developed abdominal pain and, on computed tomography, was found to have multiple intraabdominal foci of disease.
  • A 18 fluorodeoxyglucose positron emission tomography scan showed no pathological uptake.
  • CONCLUSIONS: Aggressive multimodal management appears to be the most promising approach for malignant thyroid tissue arising in ovarian teratomas.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Thyroid cancer, follicular.
  • Genetic Alliance. consumer health - Thyroid cancer, papillary.
  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. LEVOTHYROXINE .
  • Hazardous Substances Data Bank. LITHIUM, ELEMENTAL .
  • Hazardous Substances Data Bank. THYROGLOBULIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2009 Jun 18;360(25):2680-1; author reply 2682-3 [19537322.001]
  • [Cites] Endocr Pract. 2009 Mar;15(2):167-73 [19289330.001]
  • [Cites] Histopathology. 2009 Oct;55(4):482-7 [19817905.001]
  • [Cites] Endocr Pathol. 2010 Jun;21(2):144-7 [19898969.001]
  • [Cites] Gynecol Oncol. 2000 May;77(2):225-6 [10785468.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Aug;86(8):3512-5 [11502772.001]
  • [Cites] Gynecol Oncol. 2001 Sep;82(3):575-7 [11520159.001]
  • [Cites] Gynecol Oncol. 2002 Aug;86(2):231-4 [12144834.001]
  • [Cites] J Reprod Med. 2003 Jan;48(1):52-6 [12611097.001]
  • [Cites] Gynecol Oncol. 2004 Jul;94(1):226-8 [15262148.001]
  • [Cites] Clin Nucl Med. 1988 Dec;13(12):866-8 [3246114.001]
  • [Cites] J Clin Endocrinol Metab. 1989 Jul;69(1):186-90 [2499590.001]
  • [Cites] Int J Gynaecol Obstet. 1993 Aug;42(2):143-6 [7901063.001]
  • [Cites] Int J Gynecol Pathol. 1993 Oct;12(4):333-43 [8253550.001]
  • [Cites] Pathol Res Pract. 1994 Nov;190(11):1082-5; discussion 1086-8 [7746743.001]
  • [Cites] Histopathology. 1997 Sep;31(3):289-90 [9354902.001]
  • [Cites] J Postgrad Med. 1996 Apr-Jun;42(2):39-42 [9715297.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Mar;84(3):912-6 [10084570.001]
  • [Cites] Gynecol Oncol. 2005 Apr;97(1):282-4 [15790478.001]
  • [Cites] Curr Opin Obstet Gynecol. 2005 Jun;17(3):299-308 [15870565.001]
  • [Cites] Hum Pathol. 2005 Jun;36(6):694-7 [16021577.001]
  • [Cites] Int J Gynecol Cancer. 2005 Nov-Dec;15(6):1156-9 [16343201.001]
  • [Cites] Thyroid. 2005 Dec;15(12):1355-61 [16405408.001]
  • [Cites] Pathology. 2007 Feb;39(1):139-46 [17365830.001]
  • [Cites] Gynecol Oncol. 2007 May;105(2):321-4 [17240432.001]
  • [Cites] Int J Surg Pathol. 2007 Apr;15(2):116-20 [17478764.001]
  • [Cites] Am J Surg Pathol. 2007 Sep;31(9):1337-43 [17721188.001]
  • [Cites] Endocr Pathol. 2007 Fall;18(3):182-6 [18058267.001]
  • [Cites] Clin Nucl Med. 2008 Apr;33(4):247-50 [18356660.001]
  • [Cites] Int J Gynecol Pathol. 2008 Apr;27(2):213-22 [18317221.001]
  • [Cites] Gynecol Endocrinol. 2008 Jun;24(6):312-9 [18584410.001]
  • [Cites] Ultrasound Obstet Gynecol. 2008 Aug;32(2):210-9 [18636616.001]
  • [Cites] Ceylon Med J. 2008 Jun;53(2):55-6 [18678124.001]
  • [Cites] Int J Gynecol Pathol. 2008 Oct;27(4):496-506 [18753973.001]
  • [Cites] Obstet Gynecol Surv. 2008 Nov;63(11):725-32 [18928577.001]
  • [Cites] Cancer Genet Cytogenet. 2009 Apr 1;190(1):15-20 [19264228.001]
  • [Cites] Thyroid. 2009 Oct;19(10):1093-8 [19732012.001]
  • (PMID = 20718682.001).
  • [ISSN] 1557-9077
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Intramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iodine Isotopes; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 9010-34-8 / Thyroglobulin; 9FN79X2M3F / Lithium; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf; Q51BO43MG4 / Thyroxine
  • [Other-IDs] NLM/ PMC2964358
  •  go-up   go-down


Advertisement
4. Lee YK, Choi CG, Lee JH: Atypical teratoid/rhabdoid tumor of the cerebellum: report of two infantile cases. AJNR Am J Neuroradiol; 2004 Mar;25(3):481-3
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Despite intensive chemotherapy and radiation therapy, both of our two patients died within 8 months of pathologic diagnosis.
  • [MeSH-major] Cerebellar Neoplasms / congenital. Magnetic Resonance Imaging. Rhabdoid Tumor / congenital. Teratoma / congenital. Tomography, X-Ray Computed
  • [MeSH-minor] Biomarkers, Tumor / analysis. Cerebellum / pathology. Combined Modality Therapy. Dominance, Cerebral / physiology. Fatal Outcome. Female. Follow-Up Studies. Fourth Ventricle / pathology. Humans. Infant. Kidney Neoplasms / congenital. Kidney Neoplasms / diagnosis. Kidney Neoplasms / pathology. Kidney Neoplasms / therapy. Male. Medulla Oblongata / pathology. Neoplasms, Multiple Primary / congenital. Neoplasms, Multiple Primary / diagnosis. Neoplasms, Multiple Primary / pathology. Neoplasms, Multiple Primary / therapy

  • Genetic Alliance. consumer health - Rhabdoid tumor.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15037476.001).
  • [ISSN] 0195-6108
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


5. Selle B, Furtwängler R, Graf N, Kaatsch P, Bruder E, Leuschner I: Population-based study of renal cell carcinoma in children in Germany, 1980-2005: more frequently localized tumors and underlying disorders compared with adult counterparts. Cancer; 2006 Dec 15;107(12):2906-14
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The characteristics of RCC-affected children and their tumors, the influence of treatment, and outcome have so far not been studied in a nonselected, population-based cohort.
  • In about every third child possibly RCC-related underlying disorders (tuberous sclerosis, neuroblastoma, teratoma with chemotherapy, Saethre-Chotzen syndrome, chronic renal failure) or related diseases in their family were found.
  • The pathologic subtypes were papillary in 16 (33%), translocation type in 11 (22%), unclassified in 8 (16%), and rarely clear-cell (n = 3) or others.
  • Two of 4 patients with distant metastases received immunotherapy combined with chemotherapy and surgery, both are alive, 1 of them disease-free for 6.9 years.
  • [MeSH-major] Carcinoma, Renal Cell / pathology. Carcinoma, Renal Cell / therapy. Kidney Neoplasms / pathology. Kidney Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Cohort Studies. Female. Germany. Humans. Infant. Male. Neoplasm Staging. Prognosis. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 American Cancer Society.
  • (PMID = 17109448.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Evans K, Rogers T, Garrett-Cox R: A rare case of intrarenal teratoma in a 6-month-old male. Pediatr Blood Cancer; 2010 Dec 1;55(6):1207-9
MedlinePlus Health Information. consumer health - Wilms Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A rare case of intrarenal teratoma in a 6-month-old male.
  • We report a rare case of an intrarenal teratoma in a 6-month-old male.
  • According to SIOP guidelines, the diagnosis of Wilms tumor is made on clinical and imaging information only, prior to neoadjuvant chemotherapy.
  • This patient was investigated, according to UK (CCLG) guidelines, with a biopsy prior to treatment and therefore avoided unnecessary chemotherapy.
  • [MeSH-major] Kidney Neoplasms / surgery. Nephrectomy. Teratoma / surgery. Wilms Tumor / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Humans. Infant. Male. Treatment Outcome

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20979178.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Subramanian VS, Gilligan T, Klein EA: A case of spermatic cord teratoma in low-stage testicular cancer managed by surveillance. Nat Clin Pract Urol; 2008 Apr;5(4):220-3
Genetic Alliance. consumer health - Testicular cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of spermatic cord teratoma in low-stage testicular cancer managed by surveillance.
  • The patient underwent right inguinal orchiectomy and was diagnosed with nonseminomatous germ cell tumor of the right testis, composed of yolk sac tumor, teratoma, and embryonal carcinoma with no evidence of metastatic disease.
  • He opted to remain under surveillance rather than undergo primary chemotherapy or retroperitoneal lymph node dissection for his clinical stage I disease.
  • Serologic relapse at 4 months after orchiectomy was successfully treated with bleomycin, etoposide and cisplatin (BEP) chemotherapy.
  • DIAGNOSIS: A 1.7 cm nodule anterior to the right psoas muscle suspicious for metastatic disease that was seen on CT 16 months after orchiectomy was pathologically confirmed as recurrent mature teratoma in the spermatic cord.
  • Additionally, one of eleven interaortocaval lymph nodes showed evidence of teratoma.
  • [MeSH-major] Genital Neoplasms, Male / therapy. Neoplasms, Germ Cell and Embryonal / surgery. Spermatic Cord / pathology. Teratoma / therapy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chorionic Gonadotropin / blood. Disease Management. Humans. Lymph Node Excision. Lymphatic Metastasis. Male. Neoplasm Recurrence, Local / therapy. Orchiectomy. alpha-Fetoproteins / analysis

  • Genetic Alliance. consumer health - Teratoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18268549.001).
  • [ISSN] 1743-4289
  • [Journal-full-title] Nature clinical practice. Urology
  • [ISO-abbreviation] Nat Clin Pract Urol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin; 0 / alpha-Fetoproteins
  •  go-up   go-down


8. Ondrus D, Hornák M, Breza J, Mat'oska J, Schnorrer M, Belan V, Kausitz J: Delayed orchiectomy after chemotherapy in patients with advanced testicular cancer. Int Urol Nephrol; 2001;32(4):665-7
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Delayed orchiectomy after chemotherapy in patients with advanced testicular cancer.
  • INTRODUCTION: The therapeutic procedures in the management of testicular cancer are determined by histological findings in the removed testis and by the extent of the disease at the time of diagnosis.
  • However, all advanced tumors could be treated by primary chemotherapy regardless of the histological findings.
  • When the diagnosis of advanced tumor is evident, it is possible to start the treatment without orchiectomy.
  • The aim of this study was to evaluate the advantages of neo-adjuvant chemotherapy with delayed orchiectomy in the management of advanced testicular cancer.
  • MATERIAL AND METHODS: A total of 36 patients with advanced germ cell testicular cancer underwent primary PVB or BEP chemotherapy without previous orchiectomy.
  • Detailed medical, surgical and urological examination showed pulmonary metastases and/or extensive abdominal tumorous masses imitating acute abdominal crisis and impaired drainage of the kidney due to ureteral obstruction.
  • The patients were treated with cisplatin-containing combination chemotherapy.
  • Following completion of chemotherapy, orchiectomy was performed alone or simultaneously with retroperitoneal lymph node dissection (RPLND) and/or lung metastasectomy in cases with persistent residual mass.
  • Following orchiectomy the patients were regularly checked and in cases with viable malignant tumor found in the testis sequential chemotherapy was administered.
  • Similarly when the relapse of the disease was detected, the patients were treated with sequential chemotherapy.
  • RESULTS: Complete disappearance of metastases was observed in 12 patients following chemotherapy alone.
  • The viable tumor in the removed tissue was found in one patient.
  • Delayed orchiectomy was performed simultaneously with surgical removal of residual mass in the retroperitoneum in 24 patients and as a separate procedure in 12 patients who have been considered to be complete responders following chemotherapy alone.
  • Residual viable tumor in testicular specimen was found in three patients, necrotic or fibrotic tissue in 18, and mature teratoma in 15 patients.
  • Overall survival of the patients was 26/36 (72.7%) at mean of 56.9 months (range 7-145 months, median 50 months) since the start of the treatment.
  • CONCLUSIONS: In patients with advanced germ cell testicular cancer preference must be given to the early beginning of intensive chemotherapy without the need of tissue diagnosis of primary tumor that should be obtained by orchiectomy.
  • Benefit of this therapeutic approach is the timely management of acute abdominal and/or pulmonary symptoms of life-threatening distant metastases.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / therapeutic use. Cisplatin / therapeutic use. Germinoma / drug therapy. Orchiectomy. Testicular Neoplasms / drug therapy. Vinblastine / therapeutic use
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Humans. Lung Neoplasms / secondary. Male. Middle Aged. Neoplasm, Residual. Survival Rate. Teratoma / secondary. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Testicular cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1984 Sep;2(9):1025-7 [6088708.001]
  • [Cites] J Urol. 1983 Mar;129(3):522-3 [6834536.001]
  • [Cites] J Urol. 1996 Mar;155(3):952-4 [8583615.001]
  • [Cites] Br J Cancer. 1983 May;47(5):613-9 [6189504.001]
  • [Cites] Cancer. 1995 Feb 15;75(4):1018-24 [7842403.001]
  • [Cites] Ann Intern Med. 1977 Sep;87(3):293-8 [71004.001]
  • [Cites] J Urol. 1986 Dec;136(6):1221-3 [3022018.001]
  • (PMID = 11989561.001).
  • [ISSN] 0301-1623
  • [Journal-full-title] International urology and nephrology
  • [ISO-abbreviation] Int Urol Nephrol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5V9KLZ54CY / Vinblastine; Q20Q21Q62J / Cisplatin; PVB protocol
  •  go-up   go-down


9. Bakshi N, Mansoor I, Venkataramu NK, Katariya S: An unusual renal malignancy of childhood: unilateral teratoid Wilms's tumor. Pediatr Pathol Mol Med; 2003 Sep-Oct;22(5):435-41
MedlinePlus Health Information. consumer health - Wilms Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Teratoid Wilms's tumor is a rare histologic variant of the classical Wilms's tumor, containing predominantly heterolougus tissues (adipose, glial, muscle, cartilage, or bone).
  • We report an unusual variant of such tumor, which simulated renal teratoma because of abundant fat within the tumor.
  • The child underwent radical excision; postoperatively, he was treated with chemotherapy, and now the child is well at 36 months after surgery.
  • Surgery should be the treatment of choice, because the efficacy of chemotherapy and radiotherapy is probably reduced by the high amount of differentiated and mature tissue that characterizes this neoplasm.
  • [MeSH-major] Kidney Neoplasms / pathology. Teratoma / pathology. Wilms Tumor / pathology

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14692195.001).
  • [ISSN] 1522-7952
  • [Journal-full-title] Pediatric pathology & molecular medicine
  • [ISO-abbreviation] Pediatr Pathol Mol Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Inoue M, Uchida K, Kohei O, Nashida Y, Deguchi T, Komada Y, Kusunoki M: Teratoid Wilms' tumor: a case report with literature review. J Pediatr Surg; 2006 Oct;41(10):1759-63
MedlinePlus Health Information. consumer health - Wilms Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Teratoid Wilms' tumor is an unusual histologic variant of nephroblastoma in which the heterologous tissue predominates.
  • The treatment for this tumor has not been established because of its rarity and varying tumor components.
  • The tumor originated from the right kidney with multiple cysts and calcifications; renal teratoma was suspected preoperatively, and the operation was performed.
  • Anaplastic elements, tumor capsule invasion, renal sinus soft tissue invasion, or tumors in intrarenal vessels were not observed.
  • The patient was disease free for 3 years after surgery without receiving chemotherapy.
  • We selected this therapeutic approach because of the chemoresistance of this tumor and the excellent prognosis in small (<550 g) stage I/favorable-histology classical Wilms' tumor diagnosed at less than 24 months of age.
  • Therefore, nephrectomy alone may be an acceptable treatment of this stage of tumor in patients with teratoid Wilms' tumor.
  • [MeSH-major] Kidney Neoplasms / pathology. Kidney Neoplasms / surgery. Nephrectomy. Teratoma / pathology. Teratoma / surgery. Wilms Tumor / pathology. Wilms Tumor / surgery
  • [MeSH-minor] Humans. Infant. Male. Radiography, Abdominal. Tomography, X-Ray Computed. Ultrasonography

  • Genetic Alliance. consumer health - Wilms' tumor.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17011284.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 18
  •  go-up   go-down


11. Albert A, Cruz O, Montaner A, Vela A, Badosa J, Castañón M, Morales L: [Congenital solid tumors. A thirteen-year review]. Cir Pediatr; 2004 Jul;17(3):133-6
MedlinePlus Health Information. consumer health - Wilms Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This is an interesting group of tumors because their type, relative incidence, natural history and response to treatment differ from those seen in older children.
  • Treatment was surgical resection alone in 17 cases (68%) and surgery + chemotherapy in 8 (32%) (5 neuroblastomas, one CNS tumor, one Wilms tumor and one presacral teratoma who developed a yolk sac tumor); 3 patients died (11%): one at surgery, one of tumoural airway obstruction at birth and one with craniopharyngioma.
  • Among the 14 tumors that were initially not malignant, two can be locally agressive, one was an immature teratoma, the giant nevus with hamartoma developed in situ melanoma, the other nevus had meningeal melanosis with hydrocephalus, and one mature presacral teratoma developed a yolk sac tumor.
  • Complete surgical excision is the treatment of choice, most cases not need adjuvant chemotherapy.
  • [MeSH-major] Central Nervous System Neoplasms / congenital. Kidney Neoplasms / congenital. Liver Neoplasms / congenital. Neuroblastoma / congenital. Skin Neoplasms / congenital. Soft Tissue Neoplasms / congenital. Teratoma / congenital. Wilms Tumor / congenital
  • [MeSH-minor] Female. Follow-Up Studies. Humans. Infant, Newborn. Male. Neoplasm Recurrence, Local. Postoperative Complications. Pregnancy. Prenatal Diagnosis. Time Factors

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15503950.001).
  • [ISSN] 0214-1221
  • [Journal-full-title] Cirugía pediátrica : organo oficial de la Sociedad Española de Cirugía Pediátrica
  • [ISO-abbreviation] Cir Pediatr
  • [Language] spa
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


12. Cecchetto G, Alaggio R, Scarzello G, Dall'Igna P, Martino A, Bisogno G, Guglielmi M: Teratoid Wilms' tumor: report of a unilateral case. J Pediatr Surg; 2003 Feb;38(2):259-61
MedlinePlus Health Information. consumer health - Wilms Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Teratoid Wilms' tumor is a rare histologic variant of the classical Wilms' tumor, containing predominantly heterologous tissues (adipose, glial, muscle, cartilage, or bone).
  • The mass, which originated from the right kidney, was very large and encased the inferior vena cava and renal vessels.
  • Surgery should be the treatment of choice, because the efficacy of chemotherapy and radiotherapy is probably reduced by the high amount of differentiated and mature tissue which characterizes this neoplasm.
  • [MeSH-major] Kidney Neoplasms / pathology. Kidney Neoplasms / surgery. Wilms Tumor / pathology. Wilms Tumor / surgery
  • [MeSH-minor] Chemotherapy, Adjuvant. Child, Preschool. Diagnosis, Differential. Female. Humans. Magnetic Resonance Imaging. Radiotherapy, Adjuvant. Teratoma / diagnosis. Teratoma / pathology. Treatment Outcome. Vena Cava, Inferior / pathology

  • Genetic Alliance. consumer health - Wilms' tumor.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003, Elsevier Science (USA). All rights reserved.
  • (PMID = 12596119.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Sultan I, Ajlouni F, Al-Jumaily U, Al-Ashhab M, Hashem H, Ghandour K, Masarweh M, Al-Hussaini M: Distinct features of teratoid Wilms tumor. J Pediatr Surg; 2010 Oct;45(10):e13-9
MedlinePlus Health Information. consumer health - Wilms Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Teratoid Wilms tumor is an unusual variant of nephroblastoma in which heterologous tissue predominates.
  • Typically, histopathologic examination shows a mixture of mature squamous and mucus-producing columnar epithelium and a prominent component of mature adipose tissue.
  • The treatment of this tumor has not been established because of its rarity with some reports doubting the value of chemotherapy.
  • The second case was a 5-year-old girl with a metastatic tumor in association with horseshoe kidney and is the first case of teratoid Wilms tumor with brain metastasis.
  • Failure to respond to preoperative chemotherapy was seen in our patients and in most previously reported cases that were treated with preoperative chemotherapy.
  • [MeSH-major] Kidney / pathology. Kidney Neoplasms / pathology. Teratoma / pathology. Wilms Tumor / pathology
  • [MeSH-minor] Child, Preschool. Female. Humans. Infant. Male. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20920703.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


14. Zielińska E, Bodalski J: Growth retardation and osteomalacia as a result of ifosfamide nephrotoxicity in a 3-year-old boy whose genotype reveals the genes encoding glutathione S-transferases GSTM1 and GSTT1. Cytobios; 2001;106(413):193-200
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A case of a child with growth retardation and prolonged osteomalacia, as a result of chronic renal tubulopathy, following successful therapy for a sacral-coccygeal germinal tumour, is described.
  • Intense chemotherapy resulted in an increased risk of chronic side effects.
  • [MeSH-major] Antineoplastic Agents, Alkylating / adverse effects. Glutathione Transferase / deficiency. Growth Disorders / etiology. Ifosfamide / adverse effects. Kidney / drug effects. Kidney Diseases / complications. Osteomalacia / etiology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child, Preschool. Genetic Predisposition to Disease / genetics. Humans. Male. Sacrococcygeal Region / pathology. Teratoma / drug therapy. Teratoma / pathology. Treatment Outcome. Water-Electrolyte Balance / drug effects. Water-Electrolyte Balance / physiology

  • Genetic Alliance. consumer health - Osteomalacia.
  • MedlinePlus Health Information. consumer health - Growth Disorders.
  • MedlinePlus Health Information. consumer health - Kidney Diseases.
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11523744.001).
  • [ISSN] 0011-4529
  • [Journal-full-title] Cytobios
  • [ISO-abbreviation] Cytobios
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; EC 2.5.1.- / glutathione S-transferase T1; EC 2.5.1.18 / Glutathione Transferase; EC 2.5.1.18 / glutathione S-transferase M1; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


15. Rao S, Azmy A, Carachi R: Neonatal tumours: a single-centre experience. Pediatr Surg Int; 2002 Sep;18(5-6):306-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We present our experience of managing neonatal tumours in a tertiary reference centre to study the incidence, pathology and types, efficacy of treatment, and impact of antenatal diagnosis on the management in our practice in a retrospective study of case-notes and pathology reports.
  • Teratomas were the commonest type (n = 33, 40%) followed by neuroblastomas (NB) (14), renal (13), soft-tissue (10), hepatic (4), and miscellaneous tumours (2).
  • Surgery remains the mainstay of treatment.
  • Chemotherapy has also become safer.
  • Therapeutic complications were responsible for 50% of deaths before 1986; from 1986 onwards, there has been no therapy-related mortality.
  • The small numbers of neonatal tumours seen by individual centres underline the need for an international effort to optimise therapy and improve understanding of these tumours.
  • [MeSH-minor] Female. Humans. Infant, Newborn. Kidney Neoplasms / surgery. Male. Neuroblastoma / surgery. Retrospective Studies. Soft Tissue Neoplasms / surgery. Teratoma / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12415344.001).
  • [ISSN] 0179-0358
  • [Journal-full-title] Pediatric surgery international
  • [ISO-abbreviation] Pediatr. Surg. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


16. Nayak A, Iyer VK, Agarwal S, Agarwala S: Fine needle aspiration cytology of fetal rhabdomyomatous and teratoid Wilms tumor. Acta Cytol; 2010 Jul-Aug;54(4):563-8
MedlinePlus Health Information. consumer health - Wilms Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In all 5 aspirates, foci of blastema with or without tubules were identified, permitting a diagnosis of WT.
  • CONCLUSION: The outcome of fetal rhabdomyomatous and teratoid WTs is good, but the tumors do not shrink with chemotherapy.
  • Identification of rhabdomyoblastic elements on aspirates can help in assessment of subsequent response to treatment.
  • [MeSH-major] Kidney Neoplasms / pathology. Neoplasms, Multiple Primary / pathology. Rhabdomyoma / pathology. Teratoma / pathology. Wilms Tumor / pathology
  • [MeSH-minor] Biopsy, Fine-Needle. Child, Preschool. Female. Humans. Infant. Male. Nephrectomy. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20715657.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Miniati D, Gay AN, Parks KV, Naik-Mathuria BJ, Hicks J, Nuchtern JG, Cass DL, Olutoye OO: Imaging accuracy and incidence of Wilms' and non-Wilms' renal tumors in children. J Pediatr Surg; 2008 Jul;43(7):1301-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The nWT group included congenital mesoblastic nephroma (5), clear cell sarcoma (4), neuroblastoma (4), renal cell carcinoma (4), lymphoma (2), angiomyolipoma (2), teratoma (1), hemangioma (1), and renal epithelial tumor (1).
  • Sensitivity, specificity, positive predictive value, and negative predictive value for computed tomography (CT) determining a diagnosis of WT were 0.92, 0.55, 0.84, and 0.73, respectively.
  • These data have significant implications for parental counseling, surgical plan, and the choice of neoadjuvant chemotherapy and argue in favor of obtaining a tissue diagnosis before instituting therapy.
  • [MeSH-major] Kidney / pathology. Kidney Neoplasms / diagnosis. Wilms Tumor / diagnosis

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18639686.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Arda IS, Tüzün M, Demirhan B, Sevmis S, Hicsönmez A: Lumbosacral extrarenal Wilms' tumour: a case report and literature review. Eur J Pediatr; 2001 Oct;160(10):617-9
MedlinePlus Health Information. consumer health - Wilms Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The exact mechanism whereby a WT occurs in extrarenal tissues is not known.
  • However the histological characteristics are the same as in intrarenal WT, a retroperitoneal teratoma should be clearly investigated for a possible admixture of WT cells.
  • Patients with extrarenal WT are given the same treatment protocol as patients with stage III WT.
  • Surgical excision is the treatment of choice and the same general therapeutic rules should be followed as when the kidney were affected.
  • Stage III guidelines for chemotherapy and radiotherapy are appropriate in these patients.
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Child, Preschool. Female. Humans. Lumbosacral Region. Tomography, X-Ray Computed. Ultrasonography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11686507.001).
  • [ISSN] 0340-6199
  • [Journal-full-title] European journal of pediatrics
  • [ISO-abbreviation] Eur. J. Pediatr.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 22
  •  go-up   go-down


19. Lawrenz B, Schiller H, Willbold E, Ruediger M, Muhs A, Esser S: Highly sensitive biosafety model for stem-cell-derived grafts. Cytotherapy; 2004;6(3):212-22
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The recent success in the derivation of differentiated cell types from stem cells has raised prospects for the application of regenerative cell therapy.
  • We either injected 1 million viable cells into the kidney capsule, or mixed 2 million cells with Matrigel for s.c. transplantation.
  • RESULTS: The nude mouse model reproducibly allowed detection of 20 tumorigenic cells, and even as few as 2 ES cells were found to form teratoma.
  • The highest level of sensitivity (100% detection of 20 tumorigenic ES cells) was achieved by s.c. injection of cells mixed with Matrigel.
  • [MeSH-minor] Animals. Cell Line. Cell Transformation, Neoplastic / immunology. Clone Cells / drug effects. Clone Cells / immunology. Collagen / pharmacology. Drug Combinations. Immune Tolerance / immunology. Laminin / pharmacology. Mice. Mice, Inbred BALB C. Models, Animal. Neoplasms / immunology. Neoplasms / prevention & control. Predictive Value of Tests. Proteoglycans / pharmacology. Reproducibility of Results

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15203978.001).
  • [ISSN] 1465-3249
  • [Journal-full-title] Cytotherapy
  • [ISO-abbreviation] Cytotherapy
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Laminin; 0 / Proteoglycans; 119978-18-6 / matrigel; 9007-34-5 / Collagen
  •  go-up   go-down


20. Luque Mialdea R, Martín-Crespo R, Hernández E, Sánchez O, Cañizo A, Fernández A, Aparicio C, Blanco T, Cebrían J: [Use of oral anticholinergic therapy in children under 1 years of age with high risk bladder]. Cir Pediatr; 2005 Jan;18(1):3-7
Hazardous Substances Data Bank. OXYBUTYNIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Use of oral anticholinergic therapy in children under 1 years of age with high risk bladder].
  • THE AIM: To assess the effectiveness and safety of the treatment with oral anticholinergic agents (Oxybutin clorure) in patients under 1 year old, and who aree carriers of high risk bladder secondary to neurological illness as well as no neurological one.
  • MATERIAL AND METHODS: Since 1989, we have indicated treatment with anticholinergic agents to 16 patients: 9 patients had neurogenic bladder secondary to: myelomeningocele (n=7) and sacrocoxigeal teratoma (n=2).
  • All patients at treatment with anticholinergic agents at a 0.2 mg/kg/day dose was established; other early adjunctive treatment prior to the closure of the urinary derivation in children with CRF(n=5); or as a part of the conservative treatment (n=3), alone or associate to intermittent bladder catheterization (IBC) (n=8).
  • During the treatment with anticholinergic agents, the cardiac frequency was controlled by EKG registration in 6 patients, being the rest of the children clinicaly controled (skin colour, mouth dryness, cardiac frequency and intestinal function).
  • RESULTS: In all the cases, the minimum duration of the treatment was one year, until the functional stabilization of the urinary tract.
  • It is to underline the absence of secondary complications which would have caused the suspension or the reduction of the treatment at long term.
  • Conventional studies of urologicals image and urodinamic studies, showed the stabilization of the urinary tract and also the preservation of kidney function and not only was demonstrated in those patients with oral anticholinergic agent as their unique treatment, but also in those patients who had previously been derivated.
  • In cases with previous derivation, the treatment with oral anticholinergic agents made easier vesicostomic clousure in the forth quarter of the first year old wih the maintenance of the vesical stability.
  • CONCLUSIONS: The use of oral anticholinergic agents at a dose of 0.2 mg/kg/day, has resulted to be safe as well as effective in the treatment of high risk bladder in infancy those with less than one year of life.
  • In those patients with serious dysplasia by reflux, it contributes to the preservation of kidney function, it makes easier the early desderivation and it also stabilizes in a functional way the bladder as a previous step to subsequent reconstructive surgeries.
  • [MeSH-major] Cholinergic Antagonists / therapeutic use. Mandelic Acids / therapeutic use. Urinary Bladder, Neurogenic / drug therapy. Urinary Bladder, Neurogenic / physiopathology
  • [MeSH-minor] Child. Drug Administration Schedule. Electrocardiography. Humans. Infant. Risk Factors. Urodynamics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15901100.001).
  • [ISSN] 0214-1221
  • [Journal-full-title] Cirugía pediátrica : organo oficial de la Sociedad Española de Cirugía Pediátrica
  • [ISO-abbreviation] Cir Pediatr
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Cholinergic Antagonists; 0 / Mandelic Acids; K9P6MC7092 / oxybutynin
  •  go-up   go-down






Advertisement